Influence of SGLT2 inhibitor on myocardial fatty acid metabolism

Investigation of Influence of SGLT2 inhibitor on myocardial fatty acid metabolism using BMIPP SPECT - ISMFAM

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1041190002

Enrollment

Registered

2019-04-04

Start date

2019-04-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Fatty acid metabolic myocardial SPECT is performed on patients newly given or not receiving canagliflozin.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetic patients with cardiac dysfunction, diastolic dysfunction or cardiac abnormalities

Exclusion criteria

Exclusion criteria: Patients who did not meet the selection criteria

Design outcomes

Primary

Measure	Time frame
Myocardial fatty acid metabolism six months later, one year later	—

Contacts

Public ContactSoichi Takeishi

Inuyama Chuo General Hospital

souichi19811225@yahoo.co.jp+81-568-62-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026